Introduction {#sec1-1}
============

Polycystic ovarian syndrome (PCOS) is a most prevalent endocrinopathy which affects 4%--8% of women of reproductive age.\[[@ref1]\] Forty percent of women have anovulatory infertility due to PCOS.\[[@ref2]\] In this condition, hormonal imbalance affects follicular growth during the ovarian cycle causing the affected follicles to remain in immature form, leading to multiple ovarian cysts associated with obesity, oligomenorrhea, etc. Incidence of this disease is increasing nowadays because of sedentary lifestyle, pollution and excessive intake of junk food.\[[@ref3]\]

In Ayurveda, such type of condition can be correlated under the broad heading of *Artava Kshaya*, as oligomenorrhea is the most common symptom affecting 85%--90% of PCOS patients.\[[@ref4]\] The treatment advised for *Artava Kshaya* includes *Samshodhana* (bio purification) followed by *Agneya* drug and is the line of treatment according to *Acharya Sushruta*.\[[@ref5]\] In further commentary on *Sushruta Samhita, Dalhana* describes *Vamana Chikitsa* (therapeutic emesis) for the same. For this purpose, *Ikshwaaku* seed formulation was specifically selected for *Vamana Karma* (therapeutic vomiting) as it is advised for *Kapha* and *Granthi Vikara* (cystic swellings).

*Shatapushpadi Ghanavati* \[[Table 1](#T1){ref-type="table"}\] contains *Agni Mahabhuta* (fire element) predominant drugs, which corrects the residual pathology in the context of PCOS.

###### 

Contents of *Shatapushpadi Ghanavati*
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Aims and objectives {#sec2-1}
-------------------

To evaluate the efficacy of *Vamana* (therapeutic vometing) followed by *Shatapushpadi Ghanavati* on *Artava Kshaya* (loss of menstrual fluid) in relation to PCOS and to assess the findings based on ultrasonography (USG), obesity (body weight, body mass index \[BMI\], waist-hip ratio \[WHR\]) and blood sugar level in relation to PCOS.

Materials and Methods {#sec1-2}
=====================

A total of 15 female patients fulfilling the criteria for diagnosis of *Artava Kshaya* and PCOS were selected from the Outpatient and Inpatient Department of Panchakarma, National Institute of Ayurveda, Jaipur. Ethical clearance was obtained from Institutional Ethics Committee, dated November 7, 2014 (Approval number F10 (5)/EC/2014/7218), before commencement of the study. Informed consent was taken from each registered patient before starting the treatment. The trial is also registered in the Clinical Trial Registry of India (trial no: CTRI/2017/02/007825).

Study protocol {#sec2-2}
--------------

Study type: InterventionalPurpose: TreatmentMasking: Open labelTiming: ProspectiveEndpoint: Efficacy and safetyNumber of groups: OneNumber of patients: 15 patients.

Drugs used in the trial {#sec2-3}
-----------------------

All the medicines were procured from NIA Pharmacy, Jaipur, except *Ikshwaaku* fruit \[[Figure 1](#F1){ref-type="fig"}\], which was collected from post Aagadgaon, district Ahmednagar, Maharashtra (authenticated by the Department of Botany, Rajasthan University, Jaipur, with authentication number RUBL211524 dated April 11, 2015).

![*Ikshwaaku* fruit](AYU-38-127-g002){#F1}

Total duration of trial {#sec2-4}
-----------------------

The trial duration was 2 months.

Diagnostic criteria {#sec2-5}
-------------------

Patients fulfilling the revised Rotterdam criteria (2003) were included.

The criteria state that two out of the following three criteria should be present in the diagnosis of PCOS:

Oligo-anovulationClinical and/or biochemical hyperandrogenismPolycystic ovaries in USG (antral follicle count ≥12 and/or ovarian volume \>10 ml).

Inclusion criteria {#sec2-6}
------------------

Age group 20--40 years (unmarried and married patients)Diagnosed cases of PCOSIrregular menses/scanty menses due to anovulatory cyclePatient fit for *Vamana Karma*.

Exclusion criteria {#sec2-7}
------------------

Cervical tumor, polyp, carcinoma cervixUterine fibroidCongenital anomalies of female genital tractTuberculous endometritisCongenital adrenal hyperplasiaHIV/venereal disease research laboratory/HbsAg positiveMalignant disease and patients on cytotoxic drugsPatient not fit for *Vamana Karma*.

Laboratory investigations {#sec2-8}
-------------------------

Following investigations were carried out before and after treatment.

Fasting blood sugar (FBS) levelPostprandial blood sugar (PPBS) levelUSG (abdomen and pelvis)Physical parameters such as body weight, BMI and WHR were also assessed.

Methodology {#sec2-9}
-----------

### Procedure {#sec3-1}

*Vamana Karma* (therapeutic emesis)

*Vamana Karma* was administered in the following steps.

*Panchakola* powder\[[@ref6]\] was used for *Deepana* and *Pachana* in the dosage of 3 g twice in a day before food for 3--7 days with lukewarm water followed by *Snehapana* (administration of oil orally) with *Murchita Tila Taila*\[[@ref7]\] with initial 30 ml dose, increasing day by day according to *Agni* (digestive fire) and *Koshtha* (bowl motion habit) of the patient till *Samyak Snigdha Lakshana* (symptoms of complete oleation on body) were obtained. *Dashamoola Taila* was used for external therapeutic massage of oil to the entire body and *Dashamoola Kwatha* were used for external complete body massage with medicated oil for 2 days prior and on the day of *Vamana*.

Administration of *Vamana Yoga-Ikshwaaku* seed powder in the dosage of *5--* 7 g with other conventional drugs such as *Yashtimadhu* (*Glycyrrhiza glabra* Linn.), *Vacha (Acorus calamus* Linn.), rock salt and honey.

### Samsarjana Karma {#sec3-2}

The specific diet plan was advised to the patient according to *Avara, Madhyama* and *Pravara Shuddhi* (low, medium and complete purification level) after classical *Vamana* procedure.

### Follow-up {#sec3-3}

*Shatapushpadi Ghanavati* (compounded formulation) was given for 45 days in the dose of 1 g (2 tablets each of 500 mg) for 2 times a day 1 or ½ h before food with lukewarm water.

Assessment criteria {#sec2-10}
-------------------

### Objective parameters {#sec3-4}

Blood sugar (fasting and postprandial)Body weight, BMI, WHRUSG (includes endometrial thickness \[ET\], ovarian volume and number of nondominant follicles \[NDF\]).

### Subjective parameters {#sec3-5}

Menstrual irregularities (includes duration, interval and pain associated with menses)AcneHirsutism (based on Ferriman--Gallwey score). A special scoring pattern was adopted for assessment of subjective parameters \[[Table 2](#T2){ref-type="table"}\].

###### 

Scoring pattern of subjective parameters
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Statistical analysis {#sec2-11}
--------------------

Student\'s paired *t*-test was applied for objective parameters. Wilcoxon sign-rank test was applied out for analysis of all subjective parameters.

The obtained results were interpreted as follows:

\>0.10 nonsignificant (NS)\<0.05 significant\* (S)\<0.01 very significant\*\* (VS)\<0.001 highly significant\*\*\*\< 0.0001 extremely significant\*\*\*\* (ES).

Statistical software used {#sec2-12}
-------------------------

GraphPad InStat for Windows version 3.06, La Jolla, CA, USA, was used.

Observations {#sec2-13}
------------

All patients had chief complaint of menstrual abnormalities, 33.33% patients had positive family history of diabetes, 73.33% patients had chronicity of PCOS \>5 years. History of hair fall was noted in 76.66% of patients. Maximum patients 73.33% had hormonal therapy as treatment history, maximum patients (60%) reported consumption of *Madhura Rasa* dominant diet, 46.67% patients were taking *Snigdha Ahara* (fatty foods like milk products, etc.). 66.67% of the patients were addicted to tea, 60% were suffering from stress. All patients were having *Artava Vaha Srotas Dushti* (vitiated channels of female reproductive system) and 80% had history of not doing any physical exercise \[[Graph 1](#F2){ref-type="fig"}\].
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Results {#sec1-3}
=======

Effect of therapy on subjective parameters {#sec2-14}
------------------------------------------

Out of 15 patients statistically extremely significant (ES) results were found in prolonged interval of menses (42.91%), very significant (VS) result in delayed menses (55.68%), significant result in painful menses (52.76%), nonsignificant (NS) changes in acne (85%) and significant changes were observed in hirsutism (4.8%) \[[Table 3](#T3){ref-type="table"}\].

###### 

Effect of therapy on subjective parameters
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Effect of therapy on ultrasonography {#sec2-15}
------------------------------------

Statistically results were found in mean effect of therapy (ET) (8.19%) and ovarian volume (right \[32.66%\] and left \[15.77%\] side of ovary). Statistically significant changes were observed in mean NDF of right (26.39%) and left (21.42%) side of the ovary after *Vamana* followed by *Shatapushpadi Ghanavati* \[[Table 4](#T4){ref-type="table"}\].

###### 

Effect of therapy on ultrasonographical parameter
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Effect of therapy on other parameters {#sec2-16}
-------------------------------------

### Effect of therapy on blood sugar {#sec3-6}

Out of 15 patients, significant change in FBS was noted in 8.33% patients and NS results were observed in PPBS in 5.56% patients \[[Table 5](#T5){ref-type="table"}\].

###### 

Effect of therapy on blood sugar
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### Effect of therapy on body weight, body mass index, and waist-hip ratio {#sec3-7}

In the present clinical study, statistically ES result was found in body weight (5.54%) and BMI (5.55%). Non-significant change was observed in WHR (0.83%) \[[Table 6](#T6){ref-type="table"}\].

###### 

Effect of therapy on body weight, body mass index, and waist-hip ratio
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Overall effect of therapy on subjective parameter {#sec2-17}
-------------------------------------------------

### On menstrual disorder {#sec3-8}

Of 15 patients, 3 (20%) patients got complete remission, 2 (13.33%) patients got moderate improvement, 5 (33.33%) patients got mild improvement and 4 (26.66%) patients had no improvement at all.

### Acne {#sec3-9}

Of 15 patients, 3 (20%) patients got complete remission, 1 (6.66%) patient had mild improvement and 11 (73.33%) patients remain unchanged.

Hirsutism {#sec2-18}
---------

Of 15 patients, all remained unchanged \[[Graph 2](#F3){ref-type="fig"}\].
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Discussion {#sec1-4}
==========

Effect of therapy on primary outcome measures {#sec2-19}
---------------------------------------------

The primary outcome of therapy is regularization of menstrual cycle in relation to interval, duration and pain associated with it. ES results (*P* = 0.0010) were found in interval of menses, VS (*P* = 0.004) in duration of menses, and significant result (*P* = 0.015) in pain associated with menses. *Artava Kshaya* results due to vitiation of *Rasa Dhatu* (plasma and lymphatic tissues) and involvement of *Kapha* and *Vata*. *Vamana* is *Srotoshodhaka* (clearing micro-channels in the body) in nature. *Shatapushpadi Ghanavati* has *Deepana* (Stomachic), *Pachana* (Digestant), *Agni Deepana* (increases digestive procedures) and *Artava Janana* (regularize menstruation) properties. Hence, *Vamana* followed by *Shatapushpadi Ghanavati* removes the obstruction of flow of *Vata* and increases the *Artava Dhatu* (female reproductive tissues) qualitatively as well as quantitatively which help in menstrual irregularities.

The *Vamana* drug *Ikshwaku* has testosterone-lowering effect which may decrease the androgen level of body. Hence, after *Vamana*, significant relief in hirsutism (*P* = 0.03) was observed.

Effect of therapy on secondary outcome measures {#sec2-20}
-----------------------------------------------

Significant result (*P* = 0.01 for right ovary and *P* = 0.03 for left ovary) was found in decreasing number of NDFs. *Vamana* with *Ikshwaaku* has testosterone-lowering effect.\[[@ref8]\] The decrease level of luteinizing hormone stimulates follicle-stimulating hormone level, which is helpful in maturation of follicles. Further *Aam Pachana* (detoxification of metabolic toxins), *Agni Deepana* (increases digestion) properties of *Shatapushpadi Ghanavati* help in reducing the NDFs directly.

Effect of therapy on associated factors {#sec2-21}
---------------------------------------

The significant result (*P* = 0.02) was obtained in decrease in FBS level after completion of therapy. *Vamana Karma* along with *Shatapushpadi Ghanavati* has *Agni Deepana* (increases digestion), *Sroto Shodhaka* (clearing micro-channels in the body) properties, which indirectly increase the metabolism of liver which is the prime site of glucose metabolism. In support to this, advanced researches show that *Ikshwaku* has lipid-lowering, hypoglycemic effect.\[[@ref9]\]

ES (*P* \< 0.0001) results were found in obesity and BMI after completion of therapy. *Sthaulya* (obesity) is the *Rasapradoshaja Vikara* (disease caused due to vitiation of plasma and lymphatic tissues). As *Vamana Karma* cleanses microchannels of body, further *Shatapushpadi Ghanavati* has *Sroto Shodhaka* (clearing micro-channels in the body), *Agni Deepana* (increases digestion) and *Lekhana* (scraping) properties which scrap excess *Meda* (fat) from body and help in reducing body weight in general and BMI specifically.

Probable mode of *Vamana Karma* {#sec2-22}
-------------------------------

*Vamana Karma* is the best therapy for the elimination of *Kapha Dosha*. According to Ayurveda, PCOS may be considered as *Agni Vaishamyajanya Vikara* (disease caused due to vitiation of metabolism) in general and *Rasagni* (metabolism at *Rasa Dhatu* level) and *Medodhatvagni* (metabolism at *Meda Dhatu* level) *Mandya* deficient in particular with *Bahu Dosha Avastha* (vitiated *Dosha*). As far as *Dosha* is concerned based on the pathology and symptom complex, it is *Kapha-Vataja* disorder. Due to increased *Kapha* and *Agnimandya* (deficient metabolism), more number of follicles are produced but not matured, resulting in cyst formation causing obstruction to the flow of *Vata* in proper direction, which in turn aggravates and results into anovulation and oligomenorrhea as *Prakrita Vata* (balanced *Vata Dosha*) is responsible for proper menstruation. Hence, the treatment should be planned to correct *Agni*, eliminate vitiated excessive *Kapha Dosha* and correct *Vata Dosha* by providing proper movement of *Vata*. To eliminate vitiated *Dosha* and to improve *Agni, Samshodhana Chikitsa* (bio purification) is a preferred treatment in Ayurveda.

Further *Ikshwaaku* seed formulation was preferred for *Vamana Karma* as it is specifically mentioned for *Kapha* and *Granthi Vikara* (cystic masses).\[[@ref10]\] As PCOS is metabolic disorder, *Vamana* helps to increase metabolism of body, thereby reducing weight and specifically act on liver metabolism which is the main site of hormone formation. Furthermore, there is direct relation of estrogen and obesity. Weight loss can improve not thus increased only circulating androgen and glucose levels but also helps for ovulation and thus increases pregnancy rate in obese women with PCOS.\[[@ref11]\]

After *Samshodhana* (bio purification) to correct the residual pathology, *Shatapushpadi Ghanavati* was selected which was prepared using known *Kapha Vatahara* (pacifying *Kapha* and *Vata Dosha*), *Agni Deepana* (increases digestion), *Artava Pravartaka* (regularize menstruation) and *Garbhashaya Shodhaka* (detoxify and improves the function of uterus)drugs.

With respect to the pathology of PCOS, *Ushna* (hot), *Tikshna* (sharp), *Ruksha* (dry) and *Lekhana* (scraping) properties of the ingredients of *Shatapushpadi Ghanavati* normalizes *Kapha* vitiation and *Vatavaigunya* (vitiated *Vata Dosha*), reduces excess *Meda* (fat), removes *Srotorodha/Sanga* (blockage in micro-channels of the body) and creates normal functioning of *Apana Vata* (subtype of *Vata* which responsible for expulsion of waste) thereby regularizing the function of *Aartavavaha Srotas* as *Prakrita Vata* is responsible for proper menstrual flow.

Conclusion {#sec1-5}
==========

*Vamana Karma* followed by *Shatapushpadi Ghanavati* is effective in regularizing menstruation, achieving considerable reduction in body weight and BMI, and helpful in lowering FBS level. Thus, this treatment protocol can be useful in the management of obese PCOS patients. Further, a large sample size study may help to support the findings of the study.
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